Dexamethasone Vs Methylprednisolone for the Treatment of Patients With ARDS Caused by COVID-19

Last updated: August 17, 2020
Sponsor: Chattogram General Hospital
Overall Status: Active - Recruiting

Phase

3

Condition

N/A

Treatment

N/A

Clinical Study ID

NCT04499313
10000753
  • Ages 20-80
  • All Genders

Study Summary

A randomized clinical trial designed and intended to evaluate the efficacy of Dexamethasone and Methylprednisolone as a treatment for severe Acute Respiratory Distress Syndrome (ARDS) caused by coronavirus disease 19 (COVID-19). Our aim is to find the best option for the treatment and management of ARDS in COVID-19 patients.

Eligibility Criteria

Inclusion

Inclusion Criteria:

• Moderate to severe COVID-19 requires hospitalization. SARS-CoV-2 infection will beconfirmed by RT PCR / CT Chest in every case.

Exclusion

Exclusion Criteria:

  • Participants with uncontrolled clinical status who were hospitalized from the before.

  • Contraindication / possible drug interaction.

  • Participants who have any severe and/or uncontrolled medical conditions like, Severeischemic heart disease, epilepsy, malignancy, Pulmonary/renal/hepatic disease,pregnancy, Corpulmonale, etc.

Study Design

Total Participants: 60
Study Start date:
August 02, 2020
Estimated Completion Date:
November 30, 2020

Connect with a study center

  • Chattogram General Hospital

    Chittagong, 4000
    Bangladesh

    Active - Recruiting

  • M. Abdur Rahim Medical College Hospital

    Dinajpur,
    Bangladesh

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.